Jane Street
TELO icon

Jane Street’s Telomir Pharmaceuticals TELO Stock Holding History

Jane Street’s Portfolio TELO Stock Details TELO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,677
Closed -$15.5K – 13208
2025
Q4 		$15.5K Sell
11,677
-8,098
-41% -$11.7K ﹤0.01% 10773
2025
Q3 		$27.5K Sell
19,775
-29,781
-60% -$44.9K ﹤0.01% 10475
2025
Q2 		$61.9K Buy
+49,556
New +$115K ﹤0.01% 9116

Other funds holding TELO

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
SEM
Suncoast Equity Management Tampa, Florida $833M AUM 11.9% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
WIA
World Investment Advisors Santa Barbara, California $6.2B AUM 19.68% 1-Year Est. Return

Jane Street's TELO Position: Q1 2026 in Review

Jane Street sold out of Telomir Pharmaceuticals (TELO) in Q1 2026, closing a stake of 11,677 shares — an estimated $15.5K sold.

Jane Street first reported a position in TELO in Q2 2025 and held it in 3 quarters. The position peaked at $61.9K in Q2 2025. 27 funds tracked by Wall St. Rank hold TELO as of Q1 2026.

  • Jane Street reported no remaining Telomir Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Jane Street sold 11,677 Telomir Pharmaceuticals shares in Q1 2026, an estimated $15.5K.
  • Jane Street first reported a position in Telomir Pharmaceuticals in Q2 2025 and held it in 3 quarters.
  • Jane Street's Telomir Pharmaceuticals position peaked at $61.9K in Q2 2025.
  • 27 funds tracked by Wall St. Rank held Telomir Pharmaceuticals as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.